Кардиогенный шок при инфаркте миокарда
Аннотация
В обзоре представлены современные критерии диагностики кардиогенного шока у больных инфарктом миокарда, шкалы прогноза при этом осложнении, проанализированы современные клинические рекомендации по ведению этих пациентов, обсуждены основные результаты исследований, на которых основаны эти рекомендации, сделан акцент на спорных и необоснованных положениях рекомендаций и вопросах, требующих дальнейшего изучения.
Об авторах
Е. В. Вышлов
ФГБНУ «НИИ кардиологии», «Томский национальный исследовательский медицинский центр» РАН
Россия
Россия
В. В. Рябов
ФГБНУ «НИИ кардиологии», «Томский национальный исследовательский медицинский центр» РАН
Россия
Россия
Список литературы
1. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial Infarction: A Population-Based Perspective. Circulation. 2009;119(9):1211-9. DOI: 10.1161/CIRCULATIONAHA.108.814947
2. Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer J-C, Erne P et al. Ten-Year Trends in the Incidence and Treatment ofCardiogenic Shock. Annals ofInternal Medicine. 2008;149(9):618-26. DOI: 10.7326/0003-4819-149-9-200811040-00005
3. Aissaoui N, Puymirat E, Tabone X, Charbonnier B, Schiele F, Lefevre T et al. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries. European Heart Journal. 2012;33(20):2535-43. DOI: 10.1093/eurheartj/ehs264
4. Redfors B, Angeras O, Ramunddal T, Dworeck C, Haraldsson I, Ioanes D et al. 17-year trends in incidence and prognosis of cardiogenic shock in patients with acute myocardial infarction in western Sweden. International Journal of Cardiology. 2015;185:256-62. DOI: 10.1016/j.ijcard.2015.03.106
5. Wayangankar SA, Bangalore S, McCoy LA, Jneid H, Latif F, Karrowni W et al. Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction. JACC: Cardiovascular Interventions. 2016;9(4):341-51. DOI: 10.1016/j.jcin.2015.10.039
6. Aissaoui N, Puymirat E, Juilliere Y, Jourdain P, Blanchard D, Schiele F et al. Fifteen-year trends in the management of cardiogenic shock and associated 1-year mortality in elderly patients with acute myocardial infarction: the FAST-MI programme: Cardiogenic shock in the elderly with AMI: the FAST-MI programme. European Journal of Heart Failure. 2016;18(9):1144-52. DOI: 10.1002/ejhf.585
7. Puymirat E, Fagon JY, Aegerter P, Diehl JL, Monnier A, Hauw-Berlemont C et al. Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997-2012. European Journal of Heart Failure. 2017;19(2):192-200. DOI: 10.1002/ejhf.646
8. Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J et al. Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock. New EnglandJ ournal ofMedicine. 2012;367(14):1287-96. DOI: 10.1056/NEJMoa1208410
9. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, TalleyJD et al. Early Revascularization in Acute Myocardial Infarction Complicatedby Cardiogenic Shock. NewEnglandJournal ofMedicine. 1999;341(9):625-34. DOI: 10.1056/NEJM199908263410901
10. Ronner E, Boersma E, Laarman G-J, Somsen GA, Harrington RA, Deckers JW et al. Early angioplasty in acute coronary syndromes without persistent st-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology. 2002;39(12):1924-9. DOI: 10.1016/S0735-1097(02)01897-1
11. Wackers FJ, Lie KI, Becker AE, Durrer D, Wellens HJ. Coronary artery disease in patients dying from cardiogenic shock or congestive heart failure in the setting of acute myocardial infarction. Heart. 1976;38(9):906-10. DOI: 10.1136/hrt.38.9.906
12. Hochman JS, Buller CE, Sleeper LA, BolandJ, Dzavik V, Sanborn TA et al. Cardiogenic shock complicating acute myocardial infarction -etiologies, management and outcome: a report from the SHOCK Trial Registry. Journal of the American College of Cardiology. 2000;36(3):1063-70. DOI: 10.1016/S0735-1097(00)00879-2
13. Hasdai D, Holmes DR, Califf RM, Thompson TD, Hochman JS, Pfisterer M et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. American Heart Journal. 1999;138(1 Pt 1):21-31. PMID: 10385759
14. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. Journal of the American College of Cardiology. 2004;44(2):340-8. DOI: 10.1016/j.jacc.2004.03.060
15. Vis MM, Engstrom AE, Sjauw KD, Tjong FV, Baan J, Koch KT et al. Plasma glucose and not hemoglobin or renal function predicts mortality in patients with STEMI complicated with cardiogenic shock. Journal of Cardiovascular Medicine. 2010;11(11):827-31. DOI: 10.2459/JCM.0b013e32833cdc6d
16. Vis MM, VD Schaaf R, Sjauw K, Tijssen JG, Baan J, Koch K et al. Creatinine clearance is independently associated with one year mortality in a primary PCI cohort with cardiogenic shock. Acute Cardiac Care. 2009;11(2):107-12. DOI: 10.1080/17482940902915600
17. Andrie RP, Becher UM, Frommold R, Tiyerili V, Schrickel JW, Nickenig G et al. Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction. Critical Care. 2012;16(4):R152. DOI: 10.1186/cc11467
18. Prondzinsky R, Unverzagt S, Lemm H, Wegener N-A, Schlitt A, Heinroth KM et al. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clinical Research in Cardiology. 2012; 101 (5):375-84. DOI: 10.1007/s00392-011-0403-3
19. Attana P, Lazzeri C, Chiostri M, Picariello C, Gensini GF, Valente S. Lactate clearance in cardiogenic shock following ST elevation myocardial infarction: A pilot study. Acute Cardiac Care. 2012;14(1):20-6. DOI: 10.3109/17482941.2011.655293
20. Harjola V-P, Lassus J, Sionis A, Kober L, Tarvasmaki T, Spinar J et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock: Clinical picture and outcome of cardiogenic shock. European Journal of Heart Failure. 2015;17(5):501-9. DOI: 10.1002/ejhf.260
21. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119-77. DOI: 10.1093/eurheartj/ehx393
22. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. New England Journal of Medicine. 2010;362(9):779-89. DOI: 10.1056/NEJMoa0907118
23. Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G et al. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. Journal of the American College of Cardiology. 2018;72(2):173-82. DOI: 10.1016/j.jacc.2018.04.051
24. Overgaard CB, Dzavik V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-56. DOI: 10.1161/CIRCULA-TIONAHA.107.728840
25. Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. European Heart Journal. 2011;32(15):1838-45. DOI: 10.1093/eurheartj/ehr026
26. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. European Heart Journal. 2006;27(16):1908-20. DOI: 10.1093/eurheartj/ehi875
27. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267-315. DOI: 10.1093/eurheartj/ehv320
28. Dzavik V. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. European Heart Journal. 2003;24(9):828-37. DOI: 10.1016/S0195-668X(02)00844-8
29. Thiele H, Allam B, Chatellier G, Schuler G, Lafont A. Shock in acute myocardial infarction: the Cape Horn for trials? European Heart Journal. 2010;31(15):1828-35. DOI: 10.1093/eurheartj/ehq220
30. Mehta RH, Lopes RD, Ballotta A, Frigiola A, Sketch MH, Bossone E et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? American Heart Journal. 2010;159(1):141-7. DOI: 10.1016/j.ahj.2009.10.035
31. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35(37):2541-619. DOI: 10.1093/eurheartj/ehu278
32. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87-165. DOI: 10.1093/eurheartj/ehy394
33. Sanborn TA, Sleeper LA, Webb JG, FrenchJK, Bergman G, Parikh M et al. Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. Journal of the American College of Cardiology. 2003;42(8):1373-9. DOI: 10.1016/S0735-1097(03)01051-9
34. Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao SV. Prevalence, Predictors, and In-Hospital Outcomes of Non-Infarct Artery Intervention During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (from the National Cardiovascular Data Registry). The American Journal of Cardiology. 2009;104(4):507-13. DOI: 10.1016/j.amjcard.2009.04.016
35. Bauer T, Zeymer U, Hochadel M, Mollmann H, Weidinger F, Zahn R et al. Use and Outcomes of Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (from the EHS-PCI Registry). The American Journal of Cardiology. 2012;109(7):941-6. DOI: 10.1016/j.amjcard.2011.11.020
36. Mylotte D, Morice M-C, Eltchaninoff H, Garot J, Louvard Y, Lefevre T et al. Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction, Resuscitated Cardiac Arrest, and Cardiogenic Shock. The role of primary multivessel revascularization. JACC: Cardiovascular Interventions. 2013;6(2):115-25. DOI: 10.1016/j.jcin.2012.10.006
37. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. New England Journal of Medicine. 2017;377(25):2419-32. DOI: 10.1056/NEJMoa1710261
38. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. DOI: 10.1093/eurheartj/ehw128
39. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Connor CM, Sopko G et al. Impact of the Pulmonary Artery Catheter in Critically Ill Patients: Meta-analysis of Randomized Clinical Trials. JAMA. 2005;294(13):1664-70. DOI: 10.1001/jama.294.13.1664
40. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Medicine. 2014;40(12):1795-815. DOI: 10.1007/s00134-014-3525-z
41. Engstrom AE, Vis MM, Bouma BJ, van den Brink RBA, Baan J, Claessen BEPM et al. Right ventricular dysfunction is an independent predictor for mortality in ST-elevation myocardial infarction patients presenting with cardiogenic shock on admission. European Journal of Heart Failure. 2010;12(3):276-82. DOI: 10.1093/eurjhf/hfp204
42. Sjauw KD, Engstrom AE, Vis MM, van der Schaaf RJ, Baan J, Koch KT et al. A systematic review and meta-analysis of intraaortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? European Heart Journal. 2008;30(4):459-68. DOI: 10.1093/eurheartj/ehn602
43. Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P et al. Intra-aortic Balloon Counterpulsation and Infarct Size in Patients With Acute Anterior Myocardial Infarction Without Shock: The CRISP AMI Randomized Trial. JAMA. 2011;306(12):1329-37. DOI: 10.1001/jama.2011.1280
44. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LSD, van Domburg RT et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. European Heart Journal. 2009;30(17):2102-8. DOI: 10.1093/eurheartj/ehp292
45. Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJS et al. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction.Journal ofthe American College of Cardiology. 2017;69(3):278-87. DOI: 10.1016/j.jacc.2016.10.022
46. Sheu J-J, Tsai T-H, Lee F-Y, Fang H-Y, Sun C-K, Leu S et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Critical Care Medicine. 2010;38(9):1810-7. DOI: 10.1097/CCM.0b013e3181e8acf7
47. Tsao N-W, Shih C-M, Yeh J-S, Kao Y-T, Hsieh M-H, Ou K-L et al. Extracorporeal membrane oxygenation-assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock. Journal of Critical Care. 2012;27(5):530.e1-530.e11. DOI: 10.1016/j.jcrc.2012.02.012
48. Sakamoto S, Taniguchi N, Nakajima S, Takahashi A. Extracorporeal Life Support for Cardiogenic Shock or Cardiac Arrest Due to Acute Coronary Syndrome. The Annals of Thoracic Surgery. 2012;94(1):1-7. DOI: 10.1016/j.athoracsur.2012.01.032
49. Muller G, Flecher E, Lebreton G, Luyt C-E, Trouillet J-L, Brechot N et al. The ENCOURAGE mortality risk score and analysis of longterm outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Medicine. 2016;42(3):370-8. DOI: 10.1007/s00134-016-4223-9
50. Sattler S, Khaladj N, Zaruba M-M, Fischer M, Hausleiter J, Mehilli J et al. Extracorporal life support (ECLS) in acute ischaemic cardiogenic shock. International Journal of Clinical Practice. 2014;68(4):529-31. DOI: 10.1111/ijcp.12380
51. Bakhtiary F, Keller H, Dogan S, Dzemali O, Oezaslan F, Meininger D et al. Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock: Clinical experiences in 45 adult patients. The Journal of Thoracic and Cardiovascular Surgery. 2008;135(2):382-8. DOI: 10.1016/j.jtcvs.2007.08.007
52. Осиев А.Г., Байстрюков В.И., Бирюков А.В., Крестьянинов О.В., Редькин Д.А., Корнилов И.А. и др. Использование экстракорпоральной мембранной оксигенации при проведении экстренного чрескожного коронарного вмешательства у пациента с острым инфарктом миокарда, осложненным кардиогенным шоком. Международный журнал интервенционной кардиоангиологии. 2012;30:46-50
53. Корнилов И.А., Гражданкин И.О., Редькин Д.А., Дерягин М.Н., Ефремов С.М., Ломиворотов В.В. Экстракорпоральная мембранная оксигенация при остром инфаркте миокарда, осложненном кардиогенным шоком. Общая реаниматология. 2013;9(3):54-7
54. Дружина А.Н., Лоскутов О.А., Шлапак И.П., Тодуров Б.М. Опыт использования экстракорпоральной мембранной оксигенации в лечении острого инфаркта миокарда, осложненного кардиогенным шоком. Медицина неотложных состояний. 2015;1(64):174-8
55. Ostadal P, Rokyta R, Kruger A, Vondrakova D, Janotka M, Smid O et al. Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial. European Journal of Heart Failure. 2017;19(2):124-7. DOI: 10.1002/ejhf.857
56. van Diepen S, Cook DJ, Jacka M, Granger CB. Critical Care Cardiology Research: A Call to Action. Circulation: Cardiovascular Quality and Outcomes. 2013;6(2):237-42. DOI: 10.1161/CIRCOUTCOMES.111.969501
Рецензия
Для цитирования:
Вышлов Е.В., Рябов В.В. Кардиогенный шок при инфаркте миокарда. Кардиология. 2019;59(8):64-71. https://doi.org/10.18087/cardio.2019.8.2631
For citation:
Vyshlov E.V., Ryabov V.V. Cardiogenic Shock in Patients with Myocardial Infarction. Kardiologiia. 2019;59(8):64-71. (In Russ.) https://doi.org/10.18087/cardio.2019.8.2631
Просмотров: 4895
Послать статью по эл. почте 
Оставить комментарий 